Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates,Infants,and At-Risk Young Children

Abstract

Objective:

Review available data from clinical trials of nirsevimab for efficacy and safety in the setting of respiratory syncytial virus (RSV) prophylaxis in infants and children, while exploring nirsevimab’s role in clinical practice and highlighting continuing questions.

Data sources:

A literature search of PubMed was conducted utilizing the phrases “nirsevimab” and “medi8897.” Additional references were identified through found references. Organizational guidelines, medication labeling, and regulatory organization presentations were utilized.

Study selection and data extraction:

Relevant clinical trials investigating nirsevimab in infants and children were included as well as other references on pharmacology, pharmacokinetics, and pharmacoeconomics.

Data synthesis:

Nirsevimab, a once-a-season monoclonal antibody, demonstrated a 79.5% (95% CI, 65.9-87.7; P < 0.00001) lower incidence of RSV-associated medically attended lower respiratory tract infections (MA RSV-associated LRTI) and 77.3% (95% CI, 50.3-89.7; P = 0.0002) reduction in hospitalizations for RSV-associated MA-LRTI across 2 placebo-controlled studies. Nirsevimab demonstrated comparable safety to placebo with minor dermatologic reactions being the most common adverse event (0.9% vs 0.6%).

Relevance to patient care and clinical practice in comparison with existing agents:

Nirsevimab was approved by the US Food and Drug Administration, and recommended by the Advisory Committee on Immunization Practices and American Academy of Pediatrics for broad administration to infants entering their first RSV season and at risk patients during their second RSV season. Questions remain over efficacy in infants born < 29-week gestation and other economical considerations.

Conclusions:

Nirsevimab demonstrated clinical efficacy in reducing RSV-associated MA-LRTI and RSV-associated hospitalizations in infants and was well tolerated.

Keywords

infectious diseases monoclonal antibodies neonatology pediatrics prophylaxis viral infections

Get full access to this article

View all access options for this article.

References

Walsh

Hall

. Respiratory syncytial virus (RSV). In: Bennett

Dolin

Blaser

, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Elsevier/Saunders; 2015:1948-1960.e3. doi:10.1016/B978-1-4557-4801-3.00160-0

Wang

Blau

, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-2064. doi:10.1016/S0140-6736(22)00478-0

Centers for Disease Control Prevention. RSV surveillance & research. Updated July 27, 2023. Accessed January 19, 2024. https://www.cdc.gov/rsv/research/index.html#ref11

Kieffer

Beuvelet

Sardesai

, et al. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis. 2022;226(suppl 2):S282-S292. doi: 10.1093/infdis/jiac216

Palivizumab [package insert]. MedImmune, LLC; November 2021.

American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620-e638. doi:10.1542/peds.2014-1666

Acosta

Caballero

Polack

FP.

Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2015;23(3):189-195. doi:10.1128/CVI.00609-15

Melgar

Britton

Roper

, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4

Fleming-Dutra

Jones

Roper

, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122. doi:10.15585/mmwr.mm7241e1

10.

Beyfortus (nirsevimab-alip) [package insert]. Astrazenca AB; July 2023.

11.

American Academy of Pediatrics. ACIP and AAP recommendations for nirsevimab. August 15, 2023. Accessed September 18, 2023. https://publications.aap.org/redbook/resources/25379/AAP-Recommendations-for-the-Prevention-of-RSV

12.

Zhu

McLellan

Kallewaard

, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928. doi:10.1126/scitranslmed.aaj1928

13.

Ananworanich

Heaton

PM.

Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines. 2021;9(9):961. doi:10.3390/vaccines9090961

14.

Domachowske

Khan

Esser

, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37(9):886-892. doi:10.1097/INF.0000000000001916

15.

Griffin

Yuan

Takas

, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415-425. doi:10.1056/NEJMoa1913556

16.

Hammitt

Dagan

Yuan

, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-846. doi:10.1056/NEJMoa2110275

17.

Muller

Madhi

Seoane Nuñez

, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533-1534. doi:10.1056/NEJMc2214773

18.

Hodgson

Koltai

Krauer

, et al. Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales. Vaccine. 2022;40(49):7151-7157. doi:10.1016/j.vaccine.2022.10.041

19.

Domachowske

Madhi

Simões

EAF

, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892-894. doi:10.1056/NEJMc2112186

20.

Drysdale

Cathie

Flamein

, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425-2435. doi:10.1056/NEJMoa2309189

21.

Simões

EAF

Madhi

Muller

, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180-189. doi:10.1016/S2352-4642(22)00321-2

22.

National Library of Medicine. Evaluate the safety and tolerability, for nirsevimab in immunocompromised children (MUSIC), NCT04484935. Updated November 2023. Accessed March 1, 2024. https://clinicaltrials.gov/study/NCT04484935

23.

National Library of Medicine. A study to assess safety, pharmacokinetics anti-drug antibody and anti-RSV antibody after 2 doses of nirsevimab (JUBILUS), NCT06042049. Updated November 2023. Accessed March 1, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT06042049

24.

National Library of Medicine. Evaluate the safety and efficacy of nirsevimab in healthy preterm and term infants in China (CHIMES), NCT05110261. Updated October 2023. Accessed October 29, 2023. https://clinicaltrials.gov/study/NCT05110261

25.

Food Drug Administration. June 8, 2023: meeting of the antimicrobial drugs advisory committee meeting announcement. Updated June 8, 2023. Accessed February 14, 2024. https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2023-meeting-antimicrobial-drugs-advisory-committee-meeting-announcement-06082023

26.

López-Lacort

Muñoz-Quiles

Mira-Iglesias

, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):2400046. doi:10.2807/1560-7917.ES.2024.29.6.2400046

27.

Ernst

Bejko

Gaasch

, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29(4):2400033. doi:10.2807/1560-7917.ES.2024.29.4.2400033

28.

Centers for Disease Control and Prevention, Jones

. Evidence to recommendations framework: nirsevimab updates. Updated February 2023. Accessed September 16, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-pediatric-04-jones-508.pdf

29.

Centers for Disease Control Prevention. Vaccines for children program. Updated August 18, 2023. Accessed September 16, 2023. https://www.cdc.gov/vaccines/programs/vfc/about/index.html

30.

Wilkins

Yuan

Chang

, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023;29(5):1172-1179. doi:10.1038/s41591-023-02316-5

31.

Abryvso (Respiratory Syncytial Virus Vaccine) [package insert]. Pfizer, Inc; August 2023.

32.

Sun

Lai

, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(2):e230023. doi:10.1001/jamanetworkopen.2023.0023

33.

Palivizumab. Lexicomp online, pediatric and neonatal lexi-drugs online. UpToDate Inc.; July 30, 2021. Accessed September 18, 2023. https://online.lexi.com

34.

Respiratory Syncytial Virus Vaccine (Recombinant). Lexicomp online, pediatric and neonatal lexi-drugs online. UpToDate, Inc.; July 30, 2021. Accessed September 18, 2023. https://online.lexi.com

35.

Fullarton

Keary

Paes

, et al. Accurately assessing the expected impact of universal first respiratory syncytial virus (RSV) season immunization with nirsevimab against RSV-related outcomes and costs among all US infants. J Infect Dis. 2023;227(11):1333-1334. doi:10.1093/infdis/jiac488

36.

Centers for Disease Control and Prevention, Hutton

. Economic analysis of nirsevimab in pediatric populations. Updated February 23, 2023. Accessed September 16, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-Pediatric-02-Hutton-508.pdf

37.

Mahmud

, et al. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: a modelling study. Vaccine 2023;41:6782-6790. doi:10.1016/j.vaccine.2023.09.003

38.

Centers for Disease Control Prevention. Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season. Accessed October 29, 2023. https://emergency.cdc.gov/han/2023/han00499.asp

39.

Dagan

Hammitt

Seoane Nuñez

, et al. Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season. J Pediatric Infect Dis Soc. 2024;13(2):144-147. doi:10.1093/jpids/piad113